Hybio Pharmaceutical's Pingshan Branch Passes US FDA Inspection

MT Newswires Live

09/03

Hybio Pharmaceutical's (SHE:300199) Pingshan Branch in China passed the U.S. Food and Drug Administration's inspection after no deficiencies requiring regulatory action were found, according to a Shenzhen bourse filing on Thursday.

The routine inspection was conducted between June 18 and June 26 in compliance with current good manufacturing practice (cGMP) requirements for drug manufacturing.

The Chinese pharmaceutical company's shares slipped 1% during the afternoon trade.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2664295898"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2664295898\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2664295898?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-03 13:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664295898","market":"sh","top_or_hot":-1,"title":"Hybio Pharmaceutical's Pingshan Branch Passes US FDA Inspection","media":"MT Newswires Live","content":"<html><body><p> Hybio Pharmaceutical's (SHE:300199) Pingshan Branch in China passed the U.S. Food and Drug Administration's inspection after no deficiencies requiring regulatory action were found, according to a Shenzhen bourse filing on Thursday.</p><p>The routine inspection was conducted between June 18 and June 26 in compliance with current good manufacturing practice (cGMP) requirements for drug manufacturing.</p><p>The Chinese pharmaceutical company's shares slipped 1% during the afternoon trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hybio Pharmaceutical's Pingshan Branch Passes US FDA Inspection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHybio Pharmaceutical's Pingshan Branch Passes US FDA Inspection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-03 13:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Hybio Pharmaceutical's (SHE:300199) Pingshan Branch in China passed the U.S. Food and Drug Administration's inspection after no deficiencies requiring regulatory action were found, according to a Shenzhen bourse filing on Thursday.</p><p>The routine inspection was conducted between June 18 and June 26 in compliance with current good manufacturing practice (cGMP) requirements for drug manufacturing.</p><p>The Chinese pharmaceutical company's shares slipped 1% during the afternoon trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LABU","symbol_name":"三倍做多标普生物-Direxion","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2664295898","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664295898","pubTimestamp":1788413524,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hybio Pharmaceutical's  Pingshan Branch in China passed the U.S. Food and Drug Administration's inspection after no deficiencies requiring regulatory action were found, according to a Shenzhen bourse filing on Thursday.The routine inspection was conducted between June 18 and June 26 in compliance with current good manufacturing practice  requirements for drug manufacturing.The Chinese pharmaceutical company's shares slipped 1% during the afternoon trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300199":"翰宇药业","LABU":"三倍做多标普生物-Direxion","BK0070":"员工持股","BK4585":"ETF&股票定投概念","BK0077":"质押式回购","BK0188":"融资融券","BK0028":"国家队","BK0239":"医药制造","BK4588":"碎股"},"translate_title":"Hybio Pharmaceutical坪山分公司通过美国FDA检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300199":0.9,"LABU":1.5},"content_text":"Hybio Pharmaceutical's (SHE:300199) Pingshan Branch in China passed the U.S. Food and Drug Administration's inspection after no deficiencies requiring regulatory action were found, according to a Shenzhen bourse filing on Thursday.The routine inspection was conducted between June 18 and June 26 in compliance with current good manufacturing practice (cGMP) requirements for drug manufacturing.The Chinese pharmaceutical company's shares slipped 1% during the afternoon trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}